Table 5.
The Relationships of Cytokine Enhancement in Response to Carboplatin with Clinicopathological Features and the Clinical Responses to Chemotherapy among Ovarian/Fallopian Tube Cancer Patients.
| Clinicopathological parameters | IL-6 level after carboplatin treatment (72 h) in primary cell culture | IL-8 level after carboplatin treatment (72 h) in primary cell culture | |||||
|---|---|---|---|---|---|---|---|
| No or very little change (n=12) | Increased (>2 fold) (n=7) | P value | No or very little change (n=11) | Increased (> 2 fold) (n=8) | P value | ||
| Age (y) (n=19) | < 60 (n=12) | 7 | 5 | 0.568 | 7 | 5 | 0.96 |
| ≥ 60 (n=7) | 5 | 2 | 4 | 3 | |||
| FIGO staging (n=19) | Early (n=8) | 7 | 1 | 0.061 | 7 | 1 | 0.026* |
| Late (n=11) | 5 | 6 | 4 | 7 | |||
| Histological types (n=19) | Serous (n=13) | 7 | 6 | 0.216 | 6 | 7 | 0.127 |
| Mucinous (n=2) | 2 | 0 | 2 | 0 | |||
| Endometroid (n=3) | 3 | 0 | 2 | 1 | |||
| Granulosa (n=1) | 0 | 1 | 1 | 0 | |||
| Clinical response to chemotherapy (n=10) | Responsive (n=7) | 7 | 0 | 0.016* | 5 | 2 | 0.038* |
| Non-responsive (n=3) | 1 | 2 | 0 | 3 | |||
| Ex-vivo drug sensitivity (n=19) | EDR (n=6) | 4 | 2 | 0.502 | 3 | 3 | 0.473 |
| IDR (n=3) | 1 | 2 | 1 | 2 | |||
| LDR (n=10) | 7 | 3 | 7 | 3 | |||
EDR, extreme drug resistance; IDR, intermediate drug resistance; LDR, low drug resistance